Global Information
회사소개 | 문의 | 비교리스트

세계의 요로상피암 치료제 시장(2019-2025년)

Urothelial Cancer Treatment Market 2019-2025

리서치사 Orion Market Research Pvt Ltd
발행일 2020년 06월 상품 코드 949551
페이지 정보 영문
가격
US $ 3,600 ₩ 4,254,000 Unprintable PDF (Single User License)
US $ 4,800 ₩ 5,672,000 Printable PDF (Enterprise License)


세계의 요로상피암 치료제 시장(2019-2025년) Urothelial Cancer Treatment Market 2019-2025
발행일 : 2020년 06월 페이지 정보 : 영문

세계의 요로상피암 치료제 시장 규모는 향후(2019-2025년)에도 꾸준히 성장할 전망입니다. 특히 북미 국가에서는 의약품 가용성 개선이 제품 개발 및 임상시험 성과, 인구 고령화에 따른 관심 증대라는 요인에 의해 한층 더 시장 확대가 생기는 전망입니다.

세계의 요로상피암 치료제(Urothelial Cancer Treatment) 시장에 대해 상세하게 분석했으며, 전체적인 시장 구조와 배경(거시경제, 각종 정책 등), 주요 시장 성장 촉진요인 및 억제요인, 전체적인 시장 규모 동향 전망(향후 7년간), 치료법별·지역별 상세 동향, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 분석 개요

제2장 시장 개요와 인사이트

  • 분석 범위
  • 애널리스트의 견해와 현재 시장 동향

제3장 경쟁 환경

  • 기업 점유율 분석
  • 주요 전략 분석
  • 주요 기업 분석
    • AstraZeneca PLC
    • Bristol-Myers Squibb Co.
    • F. Hoffmann-La Roche AG
    • Merck & Co. Inc.
    • Pfizer, Inc.

제4장 시장 결정요인

  • 동기
  • 억제요인
  • 시장 기회

제5장 시장 구분

  • 세계의 요로상피암 치료제 시장 : 치료법별
    • 화학요법
    • 면역치료
    • 기타(표적치료, 방사선 요법)

제6장 지역 분석

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 스페인
    • 이탈리아
    • 프랑스
    • 기타 유럽 국가
  • 아시아태평양
    • 중국
    • 일본
    • 인도
    • 기타 아시아태평양 국가
  • 기타 국가(RoW)

제7장 기업 개요

  • Adaptimmune Therapeutics Plc
  • Alligator Bioscience AB
  • Amgen, Inc.
  • AndroScience Corp.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Co.
  • Eisai Co. Ltd.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson Service, Inc.
  • Merck & Co, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries, Ltd.
  • Teva Pharmaceutical Industries, Ltd.
  • Vault Pharma, Inc.
LSH 20.08.11

LIST OF TABLES

  • 1. GLOBAL UROTHELIAL CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)

2. GLOBAL CHEMOTHERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)

  • 3. GLOBAL IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 4. GLOBAL OTHERS THERAPYMARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 5. GLOBAL UROTHELIAL CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
  • 6. NORTH AMERICAN UROTHELIAL CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 7. NORTH AMERICAN UROTHELIAL CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)
  • 8. EUROPEAN UROTHELIAL CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)
  • 9. ASIA-PACIFIC UROTHELIAL CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)
  • 10. REST OF THE WORLD UROTHELIAL CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL UROTHELIAL CANCER TREATMENT MARKET SHARE BY THERAPY, 2018 VS 2025 (%)
  • 2. GLOBAL UROTHELIAL CANCER TREATMENT MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
  • 3. US UROTHELIAL CANCER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 4. CANADA UROTHELIAL CANCER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 5. UK UROTHELIAL CANCER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 6. FRANCE UROTHELIAL CANCER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 7. GERMANY UROTHELIAL CANCER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 8. ITALY UROTHELIAL CANCER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 9. SPAIN UROTHELIAL CANCER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 10. ROE UROTHELIAL CANCER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 11. INDIA UROTHELIAL CANCER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 12. CHINA UROTHELIAL CANCER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 13. JAPAN UROTHELIAL CANCER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 14. REST OF ASIA-PACIFIC UROTHELIAL CANCER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 15. REST OF THE WORLD UROTHELIAL CANCER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)

Global Urothelial Cancer Treatment Market Size, Share & Trends Analysis Report, by Therapy (Chemotherapy, Immunotherapy, Others) and Forecast Period 2019-2025

The global urothelial cancer treatment market is estimated to grow at a CAGR during the forecast period. The rising frequency of urothelial cancer among middle-aged people is driving the market. Urothelial cancer mostly affects older people, 90% of the urothelial cancer patients are older than 55 years and the average age of people are diagnosed with urothelial cancer is 73 years. Moreover, some crucial factors attributing to the positive growth of the market, that are economic growth, public & government awareness.

The global urothelial cancer treatment market is segmented based on the therapy type that includes chemotherapy, immunotherapy, and others. The chemotherapy segment held a significant share in the therapy segment in 2018. Geographically, the market is segmented on the basis of the region that includes North America, Europe, Asia-Pacific, and the rest of the world. North America is expected to have considerable share owing to the availability of drugs, innovations & pipelines, rising cases of urothelial cancer due to the growing geriatric population and growing public awareness.

The major players providing urothelial cancer treatment include Merck & Co. Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Pfizer Inc., Novartis AG, GlaxoSmithKline PLC, Sanofi SA, Eisai Co. Ltd. The strategies adopted by the market players include joint venture and product launches, to increase their competitiveness across a global scale. For instance,in February 2017, Bristol-Myers Squibb's Opdivo got FDA approval, this drug is used for urothelial cancer treatment. It is an intravenous injection, it can be used for the patients with locally advanced or metastatic urothelial carcinoma.

Research Methodology

The market study of the global urothelial cancer treatment market is incorporated by extensive primary and secondary research conducted by a research team. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include:

  • Reports of companies involved in the market
  • Authentic Public Databases
  • Whitepapers such as research papers and news blogs
  • Company websites and their product catalog

The report is intended for providers, suppliers, and distributors of fiberglass, for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and will serve as a source for 360-degree analysis of the market.

The Report Covers:

  • Comprehensive research methodology of the global urothelial cancer treatmentmarket.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Insights about market determinants which are stimulating the global urothelial cancer treatmentmarket.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusions

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. AstraZeneca PLC
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Bristol-Myers Squibb Co.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. F. Hoffmann-La Roche AG
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Merck & Co. Inc.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Pfizer, Inc.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Urothelial Cancer Treatment Marketby Therapy
    • 5.1.1. Chemotherapy
    • 5.1.2. Immunotherapy
    • 5.1.3. Others( Targeted Therapy & Radiation Therapy)

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Adaptimmune Therapeutics Plc
  • 7.2. Alligator Bioscience AB
  • 7.3. Amgen, Inc.
  • 7.4. AndroScience Corp.
  • 7.5. AstraZeneca PLC
  • 7.6. Bristol-Myers Squibb Co.
  • 7.7. Eisai Co. Ltd.
  • 7.8. Eli Lilly and Co.
  • 7.9. F. Hoffmann-La Roche AG
  • 7.10. GlaxoSmithKline PLC
  • 7.11. Johnson & Johnson Service, Inc.
  • 7.12. Merck & Co, Inc.
  • 7.13. Novartis AG
  • 7.14. Pfizer, Inc.
  • 7.15. Sanofi S.A.
  • 7.16. Sun Pharmaceutical Industries, Ltd.
  • 7.17. Teva Pharmaceutical Industries, Ltd.
  • 7.18. Vault Pharma, Inc.
Back to Top
전화 문의
F A Q